Home Data Calendar Blog

ZYME

Tables

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30
Common Stock Value 932.14929.40900.49886.32885.35NANA741.15NA
Weighted Average Number Of Diluted Shares Outstanding 70.5867.2866.74NA66.4866.3561.38NA52.24
Weighted Average Number Of Shares Outstanding Basic 70.5867.2866.74NA66.4866.3561.37NA51.66
Earnings Per Share Basic -0.41-0.76-0.364.77-0.72-0.97-1.18-0.76-1.17
Earnings Per Share Diluted -0.41-0.76-0.374.76-0.72-0.97-1.19-0.95-1.25

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30
Revenue From Contract With Customer Excluding Assessed Tax 16.517.0035.58402.492.635.441.9219.874.39
Revenues 16.517.0035.58402.492.635.441.9219.874.39
Costs And Expenses 49.7461.1262.8683.1052.9971.2774.6060.7265.36
Research And Development Expense 32.7739.4145.9152.9737.1056.0262.5154.8749.89
General And Administrative Expense 16.9721.7116.9530.1315.8915.2412.095.8515.47
Operating Income Loss -33.24-54.11-27.28319.39-50.36-65.82-72.69-40.85-60.96
Interest Income Expense Nonoperating Net 5.034.834.801.731.120.440.300.300.34
Income Tax Expense Benefit 1.111.651.3911.01-0.03-0.01-0.07-1.370.76
Other Comprehensive Income Loss Net Of Tax NANA0.72NANANANANANA
Net Income Loss -28.69-51.15-24.35309.43-47.85-64.62-72.62-39.15-60.58
Comprehensive Income Net Of Tax -29.17-53.03-23.63309.43-47.85-64.62-72.62-39.15-60.58
Net Income Loss Available To Common Stockholders Basic -28.69-51.15-24.35309.43-47.85-64.62-72.62-39.15-60.58
Net Income Loss Available To Common Stockholders Diluted -28.69-51.20-24.71309.42-47.86-64.62-72.93-49.42-65.12

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30
Assets 556.37602.05600.74648.73300.26NANA389.13NA
Liabilities 132.02153.13127.20155.77120.50NANA140.04NA
Liabilities And Stockholders Equity 556.37602.05600.74648.73300.26NANA389.13NA
Stockholders Equity 424.34448.92473.54492.96179.76222.28282.44249.09278.93

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30
Assets Current 374.63420.34426.37544.71190.66NANA288.22NA
Cash And Cash Equivalents At Carrying Value 94.33142.10181.58400.9196.08NANA201.87NA
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 94.33142.10181.58400.9196.08198.65275.52201.87253.44
Short Term Investments 201.07197.99159.2191.3270.16NANA50.74NA
Accounts Receivable Net Current 67.2748.8266.9233.406.73NANA15.61NA
Prepaid Expense And Other Assets Current 11.9631.4318.6619.0717.69NANA20.00NA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30
Property Plant And Equipment Gross NANANA38.01NANANA36.84NA
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment NANANA13.30NANANA14.06NA
Amortization Of Intangible Assets 0.670.680.680.530.170.170.150.15NA
Property Plant And Equipment Net 20.9022.3823.5124.7125.72NANA22.78NA
Long Term Investments 95.6792.2372.470.890.89NANA0.89NA
Finite Lived Intangible Assets Net 8.007.408.078.769.02NANA3.84NA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30
Liabilities Current 72.8593.5567.3295.6257.71NANA71.85NA
Accounts Payable And Accrued Liabilities Current 67.7969.9259.2587.4752.27NANA62.77NA
Accrued Income Taxes Current 0.831.160.840.84NANANANANA
Contract With Customer Liability Current 0.0917.762.352.35NANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30
Deferred Income Tax Liabilities Net 1.971.921.861.791.59NANA1.57NA
Other Liabilities Noncurrent 1.863.603.603.102.93NANA2.75NA
Operating Lease Liability Noncurrent 22.4123.4923.8524.6725.33NANA30.92NA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30
Stockholders Equity 424.34448.92473.54492.96179.76222.28282.44249.09278.93
Common Stock Value 932.14929.40900.49886.32885.35NANA741.15NA
Additional Paid In Capital Common Stock 154.11152.26152.68151.61169.26NANA197.71NA
Retained Earnings Accumulated Deficit -662.96-634.27-583.12-558.76-868.19NANA-683.10NA
Accumulated Other Comprehensive Income Loss Net Of Tax -8.30-7.81-5.94-6.66-6.66NANA-6.66NA
Stock Issued During Period Value New Issues NANANANANANA107.53NANA
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 2.690.742.20NA4.384.45-2.93NA10.33

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30
Net Cash Provided By Used In Operating Activities -42.67-6.40-83.19327.36-73.02-54.82-55.41-50.51NA
Net Cash Provided By Used In Investing Activities -7.02-60.67-138.22-22.07-30.43-21.9320.57-1.86NA
Net Cash Provided By Used In Financing Activities 1.9027.601.74-0.380.63-0.28108.610.69NA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30
Net Cash Provided By Used In Operating Activities -42.67-6.40-83.19327.36-73.02-54.82-55.41-50.51NA
Net Income Loss -28.69-51.15-24.35309.43-47.85-64.62-72.62-39.15-60.58
Increase Decrease In Accounts Receivable 18.46-18.1033.5226.672.31-0.15-11.3210.69NA
Share Based Compensation 2.040.372.334.504.802.90-8.18-1.69NA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30
Net Cash Provided By Used In Investing Activities -7.02-60.67-138.22-22.07-30.43-21.9320.57-1.86NA
Payments To Acquire Property Plant And Equipment 0.930.800.390.350.982.664.164.78NA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30
Net Cash Provided By Used In Financing Activities 1.9027.601.74-0.380.63-0.28108.610.69NA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30
Revenues 16.517.0035.58402.492.635.441.9219.874.39
Atreca, License NANANANA0.005.00NANANA
Jazz, Drug Supply NANA3.53NANANANANANA
Jazz, Research Support Payments And Other Service NANA30.89NANANANANANA
Jazz Pharmaceuticals Ireland Limited, Credit For Program Amendments 0.00-20.10NANANANANANANA
Jazz Pharmaceuticals Ireland Limited, Drug Supply 5.39NANANANANANANANA
Jazz Pharmaceuticals Ireland Limited, Research Support Payments And Other Service 10.0426.56NANANANANANANA
Other, Other Product NANANANA2.63NANANA0.40
Leo Pharma, Commercial Milestones,, Research And License Agreement Product One, Subsequent Event, Collaborative Arrangement NANANANANANANANANA
Leo Pharma, Commercial Milestones,, Research And License Agreement Product Two, Subsequent Event, Collaborative Arrangement NANANANANANANANANA
Leo Pharma, Development Milestone,, Research And License Agreement Product One, Subsequent Event, Collaborative Arrangement NANANANANANANANANA
Leo Pharma, Development Milestone,, Research And License Agreement Product Two, Subsequent Event, Collaborative Arrangement NANANANANANANANANA
Jazz, Delivery Of Licenses Initial Technology Transfer And B T C Data Transfer, License And Collaboration Agreement NANANA325.00NANANANANA
Leo Pharma, Upfront Fee, Research And License Agreement, Subsequent Event, Collaborative Arrangement NANANANANANANANANA
Research Support Payments And Other Service 1.080.541.163.212.630.441.92NANA
Revenue From Contract With Customer Excluding Assessed Tax 16.517.0035.58402.492.635.441.9219.874.39
Atreca, License NANANANA0.005.00NANANA
Jazz, Drug Supply NANA3.53NANANANANANA
Jazz, Research Support Payments And Other Service NANA30.89NANANANANANA
Jazz Pharmaceuticals Ireland Limited, Credit For Program Amendments 0.00-20.10NANANANANANANA
Jazz Pharmaceuticals Ireland Limited, Drug Supply 5.39NANANANANANANANA
Jazz Pharmaceuticals Ireland Limited, Research Support Payments And Other Service 10.0426.56NANANANANANANA
Other, Other Product NANANANA2.63NANANA0.40
Leo Pharma, Commercial Milestones,, Research And License Agreement Product One, Subsequent Event, Collaborative Arrangement NANANANANANANANANA
Leo Pharma, Commercial Milestones,, Research And License Agreement Product Two, Subsequent Event, Collaborative Arrangement NANANANANANANANANA
Leo Pharma, Development Milestone,, Research And License Agreement Product One, Subsequent Event, Collaborative Arrangement NANANANANANANANANA
Leo Pharma, Development Milestone,, Research And License Agreement Product Two, Subsequent Event, Collaborative Arrangement NANANANANANANANANA
Jazz, Delivery Of Licenses Initial Technology Transfer And B T C Data Transfer, License And Collaboration Agreement NANANA325.00NANANANANA
Leo Pharma, Upfront Fee, Research And License Agreement, Subsequent Event, Collaborative Arrangement NANANANANANANANANA
Research Support Payments And Other Service 1.080.541.163.212.630.441.92NANA

Plots across concepts


IncomeStatement
Operating Income Loss
Expenses
Other Nonoperating Income Expense
Balance Sheet
Finite Lived Intangible Assets Net
Assets
Goodwill
Current Assets
Prepaid Expense And Other Assets Current
NonCurrent Assets
Deferred Income Tax Assets Net
PropertyPlantAndEquipmentNet
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
Liabilities
Operating Lease Liability
Current Liabilities
Contract With Customer Liability Current
Stockholders Equity
Retained Earnings Accumulated Deficit
CashFlow
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInInvestingActivities
Net Cash Provided By Used In Investing Activities
Shares
Weighted Average Number Of Diluted Shares Outstanding
OperatingLeaseLiability
Operating Lease Liability Current
NonoperatingIncomeExpense
Other Nonoperating Income Expense
LesseeOperatingLeaseLiabilityPaymentsDue
Lessee Operating Lease Liability Undiscounted Excess Amount
FiniteLivedIntangibleAssets
Finite Lived Intangible Assets Net

Line plots across dimensions of each concept


TTM Greenblatt ROC
_
(None,)
T T M Greenblatt R O C_
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:MajorCustomers, us-gaap:ProductOrService
('zyme:JazzPharmaceuticalsIrelandLimited', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Major Customers, us-gaap: Product Or Service
us-gaap:Revenues
us-gaap:MajorCustomers, us-gaap:ProductOrService
('zyme:JazzPharmaceuticalsIrelandLimited', None)
Revenuesus-gaap: Major Customers, us-gaap: Product Or Service
us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:AwardType
(None,)
Allocated Share Based Compensation Expenseus-gaap: Award Type
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
Stockholders Equityus-gaap: Statement Equity Components
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:BalanceSheetLocation, us-gaap:FinancialInstrument
('us-gaap:ShortTermInvestments', None)
Available For Sale Securities Debt Securitiesus-gaap: Balance Sheet Location, us-gaap: Financial Instrument
us-gaap:PropertyPlantAndEquipmentGross
us-gaap:PropertyPlantAndEquipmentByType
(None,)
Property Plant And Equipment Grossus-gaap: Property Plant And Equipment By Type
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
us-gaap:BalanceSheetLocation, us-gaap:FinancialInstrument
('us-gaap:ShortTermInvestments', None)
Available For Sale Debt Securities Amortized Cost Basisus-gaap: Balance Sheet Location, us-gaap: Financial Instrument
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
Stockholders Equityus-gaap: Statement Equity Components
us-gaap:Revenues
us-gaap:MajorCustomers, us-gaap:ProductOrService
('zyme:JazzPharmaceuticalsIrelandLimited', None)
Revenuesus-gaap: Major Customers, us-gaap: Product Or Service
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:MajorCustomers, us-gaap:ProductOrService
('zyme:JazzPharmaceuticalsIrelandLimited', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Major Customers, us-gaap: Product Or Service